Summary
Johnson & Johnson (JNJ) reported a strong first quarter for 2018, with total sales reaching $20.0 billion, a 12.6% increase year-over-year. This growth was driven by robust operational performance across its segments, particularly in Pharmaceutical and Medical Devices, alongside a positive currency impact. Net earnings for the quarter were $4.37 billion, or $1.60 per diluted share, showing resilience despite increased investments and some segment-specific headwinds. The company highlighted significant growth in its Pharmaceutical segment, largely fueled by strong performance in Oncology and Pulmonary Hypertension (a new therapeutic area from the Actelion acquisition), with notable contributions from drugs like Darzalex, Imbruvica, and Zytiga. The Medical Devices segment also showed healthy growth, with Vision Care and Interventional Solutions being standout performers. While the Consumer segment saw modest growth, it faced competitive pressures and divestitures. Management's Discussion and Analysis indicates a strategic focus on innovation and growth, evidenced by continued investment in R&D and the positive impact of recent acquisitions. The company also provided an update on its ongoing restructuring initiatives aimed at optimizing operations and driving long-term efficiency. Despite ongoing litigation and regulatory environments, JNJ's financial position appears solid, with strong cash flow from operations.
Financial Highlights
53 data points| Revenue | $20.01B |
| Cost of Revenue | $6.61B |
| Gross Profit | $13.39B |
| SG&A Expenses | $5.26B |
| Interest Expense | $259.00M |
| Net Income | $4.37B |
| EPS (Basic) | $1.63 |
| EPS (Diluted) | $1.60 |
| Shares Outstanding (Basic) | 2.68B |
| Shares Outstanding (Diluted) | 2.73B |
Key Highlights
- 1Total sales of $20.0 billion, up 12.6% year-over-year, driven by strong operational growth (8.4%) and a positive currency impact (4.2%).
- 2Pharmaceutical segment sales grew by 19.4%, with Oncology and Pulmonary Hypertension (newly acquired) showing exceptional performance.
- 3Medical Devices segment sales increased by 7.5%, with Vision Care and Interventional Solutions demonstrating significant growth.
- 4Net earnings of $4.37 billion ($1.60 per diluted share), reflecting continued profitability despite increased R&D and operational investments.
- 5Operating cash flow of $3.6 billion, demonstrating the company's ability to generate substantial cash from its ongoing business activities.
- 6Progress in restructuring initiatives, with a focus on optimizing operations and driving long-term cost savings across segments, particularly within Medical Devices and Global Supply Chain.
- 7The company announced a regular quarterly cash dividend of $0.90 per share for the second quarter of 2018, indicating a commitment to returning value to shareholders.